Search Results - "Duyster, Justus"

Refine Results
  1. 1

    Anti-Angiogenics: Current Situation and Future Perspectives by Zirlik, Katja, Duyster, Justus

    Published in Oncology research and treatment (01-01-2018)
    “…Angiogenesis, the process leading to the formation of new blood vessels, is one of the hallmarks of cancer. Extensive studies established that i) vascular…”
    Get more information
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease by Spoerl, Silvia, Mathew, Nimitha R., Bscheider, Michael, Schmitt-Graeff, Annette, Chen, Sophia, Mueller, Tony, Verbeek, Mareike, Fischer, Julius, Otten, Vera, Schmickl, Martina, Maas-Bauer, Kristina, Finke, Jürgen, Peschel, Christian, Duyster, Justus, Poeck, Hendrik, Zeiser, Robert, von Bubnoff, Nikolas

    Published in Blood (12-06-2014)
    “…Graft-versus-host-disease (GVHD) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) characterized by the production of high…”
    Get full text
    Journal Article
  6. 6

    Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo by Rummelt, Christoph, Gorantla, Sivahari P., Meggendorfer, Manja, Charlet, Anne, Endres, Cornelia, Döhner, Konstanze, Heidel, Florian H., Fischer, Thomas, Haferlach, Torsten, Duyster, Justus, von Bubnoff, Nikolas

    Published in Leukemia (01-07-2021)
    “…An important limitation of FLT3 tyrosine kinase inhibitors (TKIs) in FLT3-ITD positive AML is the development of resistance. To better understand resistance to…”
    Get full text
    Journal Article
  7. 7

    Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy by KANCHA, Rama Krishna, VON BUBNOFF, Nikolas, PESCHEL, Christian, DUYSTER, Justus

    Published in Clinical cancer research (15-01-2009)
    “…Purpose: Epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) might be predictive for clinical response to EGFR inhibitor…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    MicroRNA-155–deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation by Chen, Sophia, Smith, Benjamin A.H., Iype, Joseena, Prestipino, Alessandro, Pfeifer, Dietmar, Grundmann, Sebastian, Schmitt-Graeff, Annette, Idzko, Marco, Beck, Yvonne, Prinz, Gabriele, Finke, Jürgen, Duyster, Justus, Zeiser, Robert

    Published in Blood (02-07-2015)
    “…The successful treatment of acute leukemias with allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft-versus-host disease (GVHD)…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib by Kancha, Rama Krishna, von Bubnoff, Nikolas, Bartosch, Natalie, Peschel, Christian, Engh, Richard A, Duyster, Justus

    Published in PloS one (28-10-2011)
    “…Overexpression of the ERBB2 kinase is observed in about one-third of breast cancer patients and the dual ERBB1/ERBB2 kinase inhibitor lapatinib was recently…”
    Get full text
    Journal Article
  19. 19

    A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance by Gorantla, Sivahari Prasad, Mueller, Tony Andreas, Albers‐Leischner, Corinna, Rudelius, Martina, Bubnoff, Nikolas, Duyster, Justus

    Published in Molecular oncology (01-02-2024)
    “…Tyrosine‐protein kinase (janus kinase; JAK)–signal transducer and activator of transcription (STAT) signaling plays a pivotal role in the development of…”
    Get full text
    Journal Article
  20. 20